SHANGHAI , Aug. 28, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative medicines and vaccines, today announced its interim results for the first half of 2025 along with a corporate update.

"In the first half of 2025, Everest Medicines accelerated its transformation into a leading global biopharmaceutical company by deepening our 'dual-engine' strategy," commented Rogers Yongqing Luo, CEO of Everest Medicines. " We have built a commercialization platform anchored by two blockbusters covering high-potential markets and powered by the in-house discovery and clinical translation of in vivo CAR-T and mRNA therapeutic cancer vaccine platforms ."

"Our total

See Full Page